King Abdullah University of Science and Technology
发明人:
Jasmeen Merzaban,Dina AbuSamra,Asma Al-Amoodi
申请号：
US16496880
公开号：
US20200199533A1
申请日:
2018.03.02
申请国别(地区):
US
年份:
2020
代理人:
摘要：
It has been discovered that CD34neg cells, for example HSPCs, can be modified to increase their ability to migrate and to engraft in bone marrow. One embodiment provides a method for modifying CD34neg cells by using glycosyltransferase-programmed stereosubstitution (GPS) to create relevant selectin-binding glycan determinants on the cell surface. For example, the CD34neg cells can be treated with a fucosyltransferase, such as an α(1,3)-linkage-specific fucosyltransferase. Representative enzymes that can be used include, but are not limited to fucosyltransferase VI (FTVI or FucT-6) or fucosyltransferase VII (FTVII of FucT-7). These enzymes specifically places a fucose onto a terminal type 2-lactosamine unit； if that lactosamine is capped with an α(2,3)-linked sialic acid, sLex is created.
